pre-IPO PHARMA

COMPANY OVERVIEW

EpimAb Biotherapeutics is a privately-owned biopharmaceutical R&D company based in Shanghai and Suzhou with a proprietary unique and efficient technology called FIT-Ig® (Fabs-In-Tandem Immunoglobulin) to generate bispecific molecules with antibody-like properties, without any mutations, peptide linkers, or non-Ig sequences. With this platform EpimAb is creating a pipeline of its own novel bispecific antibody therapeutics focused around immuno-oncology and other areas of high value to patients. EpimAb is also committed to diversifying its pipeline through selective licensing of its platform to partners worldwide.


LOCATION

  • Shanghai, , China

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https://www.epimab.com


    CAREER WEBSITE

    https://www.epimab.com/category/careers/


    SOCIAL MEDIA


    INVESTORS

    3e-bioventures-capital decheng-capital oriza-seed-capital trend-investment-group


    PRESS RELEASES


    Sep 19, 2023

    EpimAb Biotherapeutics to Present Initial First-in-human Data of EMB-02 at the 2023 ESMO Conference


    Jun 7, 2023

    EpimAb Biotherapeutics Appoints Yonghong Zhu, M.D., Ph.D., as Chief Medical Officer


    Jun 7, 2022

    EpimAb Biotherapeutics Announces U.S. FDA Clearance of IND Application for Phase Ib/II Trial of EMB-01 in Combination with Tagrisso for Non-Small Cell Lung Cancer


    Oct 11, 2021

    EpimAb Biotherapeutics Strengthens Scientific Advisory Board with Addition of Andrew X. Zhu


    Jul 6, 2021

    EpimAb Biotherapeutics Provides Clinical Update for EMB-02 and EMB-06


    For More Press Releases


    Google Analytics Alternative